A mathematical model for the therapy of the HIV infection by Della Rocca, G. et al.
ar
X
iv
:q
-b
io
/0
70
30
58
v1
  [
q-
bio
.PE
]  
27
 M
ar 
20
07
A mathematical model for the therapy of the HIV infection
Giulio Della Rocca∗ Marco Sammartino† and Luciano Seta ‡
Abstract
In [17] it was introduced a model to describe the dynamics of the HIV infection when the
patient is under chemotherapy (either RTI or PI). The main idea in [17] was to introduce the
effectiveness of the drug as a dynamical variable.
In this paper we pursue this idea starting from an analysis of the fitness of the virus during
the therapy. We introduce an adaptive model in which the ability of the viruses to infect
the target cells is related to the number of contacts between viruses and T–cells that have
been inhibited by the drug. This approach is similar to the model proposed in [10] for a
predator-prey system. However the biological interpretation is different here because in our
context the adaptation of the virus is due to the development of resistant virus strains. We
analyze different combination therapies with three antiviral drugs, which consist of reverse
transcriptase inhibitor (RTI) and protease inhibitor (PI) and we show the possibility of very
long latency periods, during which the viral load goes below the detectable level. These
periods are followed by a rebound followed by the re–establishing of the conditions previous
to the therapy. This dynamics is in good qualitative agreement with the available clinical
data.
Math subject classification: 92B05, 92C50, 34A99
Keywords: HIV infection, virus resistance, fitness, adaptive dynamics, ODE’s systems
1 Introduction
The dynamics of the HIV infection is a complex process that has many puzzling features.
The target of the HIV virus are the CD4+ T cells (referred as T-cells in this paper). These
cells, through the secretion of growth and differentiation factors, play a crucial role in the
immune response of the patient. When the viral attack leads the level of the T-cells below
a critical level, the result is the immunodeficiency that characterizes AIDS. In the past 15
years several mathematical models have been formulated to explain the development of the
infection in dynamical terms (see e.g. [4], [14], [5], [7], [15] and references therein). These
models, together with the design of the appropriate experiments and clinical trials, have
significantly contributed to our understanding of the processes underlying the HIV infection.
Reflecting on the fact that most HIV patients develop AIDS after several years with the
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infection, leads to the assumption that we are dealing with a slow dynamical time scale of
the infection. The mathematical modeling has significantly helped to clarify this assumption.
In fact, it is now widely recognized that the dynamics of the HIV infection evolves through
many different time scales. Mathematical modeling helped in the uncovering of these time
scales and to the assessment that they are a result of important biological processes involved
in the infection.
In the mid 1990’s, the development of potent anti-viral drugs began. The combination of
two, three and sometimes four of these drugs resulted in highly active anti-retroviral therapies
(HAART), that changed the HIV infection from a fatal disease to an illness that, in most
cases, can be chronically managed for several (up to 10-15 or more) years. The introduction
of HAART gave more momentum to mathematical modeling efforts (see [15], [9], [1], [13]
and references therein) for several reasons. In most patients under treatment, the viral load
decreased under the detectable level, leading to the hope that a carefully designed treatment
could completely eradicate the infection. Issues like: (a)dose regimen control [8], (b) the
appropriate choice of the starting time of the therapy, (c) the appropriate choice of the
combination therapy, required a quantitative understanding of the dynamics of the infection
during the therapy. We now know that complete virus eradication is still out of reach,
thus increasing the role of mathematical modeling. There is much debate in the medical
community surrounding the failure of the therapies. The existence of reservoirs (where the
virus can survive and avoid eradication, see e.g. [6]), and the development of drug resistance
(see e.g. [2]) are the two mechanisms which have gained most credit in medical literature.
The perspective we shall use in this paper is based on the assumption that the gradual
mounting of virus resistance is the underlying mechanism that drives the long term results
of HAART. To model the results of the virus resistance, some authors (see e.g. [3], [2], [18]
and [16]) have theorized that two or more virus strains coexist in an infected patient: one
that is effected by the therapy; the wild-type, and another that is resistant to therapy; the
mutant strains. Although these models have several merits, they encounter some difficulties.
The main problem is the fact that the introduction of new virus populations (the resistant
strain) necessitates the specification of a set of parameters seemingly difficult to determine
through clinical trials.
Our point of view will be different. We expect that the efficacy of therapy evolves dynam-
ically. The ideas which our analysis is based on, as expressed by (2.10) for the RTI therapy
and (2.11) for the PI therapy, are the following. First, following [12], we shall introduce
the virus population fitness and show how, in presence of the drug treatment, this fitness is
related to the effectiveness of the drug. Second, we shall assume that the fitness of the virus
population depends on an adaptive mechanism (due to the selective pressure introduced by
the presence of the drug). We quantify the strength of the selective pressure as the total
number of the viruses inhibited by the drug action. This is in analogy to [10] or [11]. These
assumptions will lead us to formulate our model equations.
The paper is organized as follows: In the next section we introduce the basic model in-
troduced by Perelson and his coworkers describing the dynamics of the infection without
therapy. After introducing the effect of the therapy as shown e.g. in [15], we derive an ODE
for the effectiveness of the therapy. This ODE has to be coupled with the equations ruling
the dynamics of the T–cells and of the viruses populations. In Section 3, we show some
numerical test where we simulate the effects of the three-therapies (resulting from different
combinations of the RTIs and PIs), In Section 4 we show that the parameters appearing in
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our model can be estimated through a careful screening of the decline of the virus load during
the first weeks of treatment. Finally we draw some conclusions.
2 The drug effectiveness
2.1 The basic model
The basic mechanism of the HIV infection is the following: a virus penetrates a T-cell, uses
the genetic material from the T-cell to produce copies of itself, and eventually kill the T-cell
to release the newly produced viruses into the blood stream to infect other T-cells.
If one denotes with T the plasma concentration of the T-cells, with T ∗ the concentration
of the infected T-cells, and with V the concentration of the HIV viruses, one can write the
following equations:
dT
dt
= s− µTT + rT
(
1−
T + T ∗
T
max
)
− kV T ; (2.1)
dT ∗
dt
= kV T − µT ∗T
∗; (2.2)
dV
dt
= NµT ∗T
∗
− cV. (2.3)
In the above equations s represents the rate of production of the T-cells. For example, due
to the bone marrow; µT is the death rate of the T-cells; the logistic term in (2.1) describes
the T-cells capability of self-reproduction; k is the rate of infection of the T-cells per unit of
virus; µT ∗ is the rate at which the viruses kill the infected T-cells; N is the number of copies
that each virus is able to produce using the genetic material of the infected T-cell.
The above parameters show strong individual variability. In the table below, we report a
set of values that are most commonly used in the literature and which we use throughout the
rest of the paper. These values are therefore to be thought as mean values.
Table 1: Parameters mean values.
s Source term for CD4+T cells 10 day−1mm−3
µT Natural death rate of CD4+T cells 0.02 day
−1
r Growth rate of CD4+T cells 0.03 day−1
T
max
Maximal population level of CD4+T cells 1500 mm3
k Rate of the infection for CD4+T cells 2.4×10−5 day−1mm3
µT ∗ Natural death rate of infected CD4+T cells 0.26 day
−1
N Number of viruses produced by infected T–cells 500
c Natural death rate of viruses 2.4 day−1
In figure 1 we have reported a simulation of the above system, where we have taken the
initial values T (0) = 1000mm−3, T ∗(0) = 0mm−3, V (0) = 10−3.
2.2 The therapies
During the ’90s, two anti-viral therapies were introduced. One was based on Reverse Tran-
scriptase Inhibitors (RTI). These drugs are able to inhibit the Reverse Transcriptase enzyme.
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Figure 1: The basic model without drugs: concentrations of uninfected T-cells, infected
T-cells and free viruses.
This enzyme is necessary to the virus in order to use the DNA of the T-cell to replicate
itself. Therefore, when the enzyme is inhibited, a virus can penetrate a T-cell but will not
successfully infect it. The model describing the dynamics of the infection under the influence
of RTI therapy is:
dT
dt
= s− µTT + rT
(
1−
T + T ∗
T
max
)
− kV T ; (2.4)
dT ∗
dt
= (1− η)kV T − µT ∗T
∗; (2.5)
dV
dt
= NµT ∗T
∗
− cV ; (2.6)
In the above equation the parameter η is the effectiveness of the drug. When η = 1 the drug
is 100% effective.
The second class of therapy is the Protease Inhibitors (PI). When the process of protease is
inhibited, the virions produced using the genetic material of the T”cells are unable to fully
mature and thus unable to reproduce. Eventually, these virions die out without contributing
to the infection. The model describing the action of the PI is:
dT
dt
= s− µTT + rT
(
1−
T + T ∗
T
max
)
− kV T ; (2.7)
dT ∗
dt
= kV T − µT ∗T
∗; (2.8)
dV
dt
= (1− δ)NµT ∗T
∗
− cV. (2.9)
In this case the effectiveness of the drug is δ.
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2.3 The drug effectiveness as a dynamical variable
In the literature both η and δ have been considered as constant. The process of virus resistance
has been described through the introduction of a new strain of viruses that are resistant to
the drug. This approach has several merits, but has the fundamental disadvantage of the
difficulty in estimating the parameters describing the new population.
Here we follow a different approach. In [12], in absence of therapy, the authors considered
kNµT ∗ (what they called the basic reproductive ratio) to be a direct measure of the fitness
of the virus population. The reason for this choice is apparent when one considers that the
reproductive capability of the viruses is proportional to both the capability to infect the T–
cells (expressed by the coefficient k) and to the number of viruses produced by each infected
T–cell (expressed by NµT ∗).
It is clear that when a therapy is introduced the fitness of the virus population is now
expressed by (1− η)kNµT ∗ and (1− δ)kNµT ∗ for RTI and PI respectively.
We now suppose that the fitness of the viruses evolves dynamically in time through an
adaptive mechanism induced by the selective pressure. In population dynamics (for example
in the case of competing species), to model adaptive mechanisms, one assumes that the fitness
increases with the total number (i.e. the integral with respect to time) of the interaction
between species. see e.g. [10][11]. By analogy we quantify the selective pressure induced by
the drug as the total number of viruses inhibited by the drug. Taking (1− η) and (1− δ) as
measures of the fitness (k, N and µT ∗ being constant), we write:
1− η(t) = ak
t∫
0
η(s)V (s)T (s) ds ; (2.10)
1− δ(t) = bNµT ∗
t∫
0
δ(s)T ∗(s) ds . (2.11)
The positive constants a and b represent the rate of growth of the resistance for the specific
drug, RTI and PI respectively. In an adaptive population dynamics setting many authors,
to model a loss of memory effect, have introduced, inside the integral, a decaying kernel. For
sake of simplicity we don’t consider this effect here.
The above formulas, that are integral equations, can be put in differential form. The resulting
model equations for the drug effectiveness are respectively:
dη
dt
= −akηV T , (2.12)
and
dδ
dt
= −bNµT ∗δT
∗ . (2.13)
Equation (2.12) has to be coupled with eqs.(2.4)–(2.6), while eq.(2.13) has to be coupled
with eqs.(2.7)–(2.9).
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3 The three–therapies
At first, the results of the therapies were encouraging. When a therapy starts, the infection
appears to experience a period of remission (that in the paper we shall call latency period),
during which the viral load decreases significantly, while the number of the T-cells increases
to the point where patients show no symptoms of the infection. After this latency period, the
viral load increases again and the condition of the patient returns to the state before therapy.
The length of the latency period is variable (usually few weeks, for mono-therapy), but for
bi-therapies or three-therapies, these latency periods become several months or several years
long. Even with multi-therapies, the latency period ends. The hope that one could eradicate
the infection with the multi-therapies has been replaced for a more realistic goal of controlling
the infection, making it a chronic condition for as long as possible.
In this section we shall see how combination therapy of three drugs can lead to a decline of
the viral load and to the increase of T-cells for periods of several thousands of days. To the
best of our knowledge, this is the first attempt of any modeling of the latency period and of
the subsequent failure of the therapy. We first consider the case of three-therapy based on
the use of two RTIs and one PI. The system that models this association of drugs is:
dT
dt
= s− µTT + rT
(
1−
T + T ∗
T
max
)
− kV T ; (3.14)
dT ∗
dt
= (1− η1)(1 − η2)kV T − µT ∗T
∗; (3.15)
dV
dt
= (1− δ)NµT ∗T
∗
− cV ; (3.16)
dη1
dt
= −a1kη
3
1V T (3.17)
dη2
dt
= −a2kη
3
2V T (3.18)
dδ
dt
= −bNµT ∗δ
3T ∗ . (3.19)
In the above equations η1 and η2 are the effectivenesses of the two Reverse Transcriptase
Inhibitors, while δ is the effectiveness of the Protease Inhibitor. The parameters that rule
how fast the HIV virus develops resistance to the drugs are a1, a2 and b respectively. In the
simulation below we have taken a1 = a2 = 1.45 × 10
−3 and b = 1.0× 10−5.
For comparison purposes in Figure 2 we show the dynamics of the infection when the
treatment is bi-therapy with two RTIs. The initial datum for T , T ∗ and V is the steady
state of the system (2.1)–(2.3). This corresponds to starting the therapy when the infec-
tion is in a mature state. For the effectiveness we assumed that at the start of therapy
η1(t = 0) = η2(t = 0) = 0.65 and η1(t = 0) = η2(t = 0) = 0.7. Through these simulations,
one can appreciate how bi-therapy causes a rapid decline of the virus load and an increase
of healthy T-cells. For a period of about three months (or about eight months when initially
the drugs are more effective) the virus load decreases below the detectable level. After this
latency period, the virus load increases as the number of T-cells decline. A rebound of the
virus load appears until the count of both the virus and the T-cells return to the initial count
before therapy. All these findings from the model are consistent with the available clinical
data.
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Figure 2: The dynamics of the infection with a bi-therapy with two RTI’s. The dashed line
represents the case of the initial effectiveness of both drugs is η(t = 0) = 0.65. The solid line
represents the case η(t = 0) = 0.7 for both drugs.
The situation is qualitatively the same for the case of the three-therapy, but quantitatively
different. In fact one can see that adding a PI to the treatment, even with a low initial
effectiveness of δ(t = 0) = 0.448, increases the latency period dramatically. This is shown
in Figure 3 where the behavior of the effectiveness of the three drugs is represented. The
latency period is about eight years long during which the virus load is very low: V ∼ 0.1
during the first 3-4 years of the therapy reaching the minimum a few weeks after starting
the therapy. Gradually, the virus load increases for several years, still remaining very low,
until a turning point is reached after which there is a violent rebound with wide oscillations.
Afterwards, the infection stabilizes at the pre-therapy level. The effectiveness of the drugs,
after an initial drop out, stabilizes for several years. Perhaps, this is a result of the drastically
low virus count after the initial stage of the therapy. The selective pressure of the drugs on
the virus population takes several years to induce significant effects. Finally, the effectiveness
drops sharply and rapidly declines to zero.
We now examine the case of a three therapy resulting from the association of one RTI and
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Figure 3: The dynamics of the infection with a three-therapy with two RTIs and one PI. The
Figure represents the case when the initial effectiveness of both the two RTIs is η(t = 0) = 0.55
while for the PI δ(t = 0) = 0.448.
two PIs. The system governing the dynamics is in this case:
dT
dt
= s− µTT + rT
(
1−
T + T ∗
T
max
)
− kV T ; (3.20)
dT ∗
dt
= (1− η)kV T − µT ∗T
∗; (3.21)
dV
dt
= (1− δ1)(1 − δ2)NµT ∗T
∗
− cV ; (3.22)
dη
dt
= −akη3V T (3.23)
dδ1
dt
= −b1NµT ∗δ
3
1
T ∗ . (3.24)
dδ2
dt
= −b2NµT ∗δ
3
2T
∗ . (3.25)
Some numerical results are shown in Figure 4. In Figure 5 we represent the viral load for
different initial effectiveness of the drugs. In the four simulations we keep η(t = 0) = 0.467,
δ1(t = 0) = 0.55 while we vary δ2(t = 0). The latency period varies significantly with a slight
change of the initial effectiveness of one PI ranging from about 6 years to about 28 years.
4 Parameter estimation and the bi-phasic decline
The main problem encountered when attempting to create a predictive model from the equa-
tions discussed in the previous sections is the estimation of parameters a and b (related to
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Figure 4: The dynamics of the infection with a three-therapy with two PIs and one RTI.
The Figure represents the case when the initial effectiveness of the two PIs is δ(t = 0) = 0.55
while for the RTI η(t = 0) = 0.467.
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Figure 5: The virus load with different initial effectiveness. In the Figure η(t = 0) = 0.467,
δ1(t = 0) = 0.55 while δ2(t = 0) = 0.548, 0.549, 0.55, 0.551, 05515. The latency period shows
a very sensitive dependence to the initial effectiveness of the drugs.
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Figure 6: The behavior of the log of the virus load during the first three weeks of a PI
mono-therapy. A bi-phasic decline is apparent. The beginning of the second phase of the
decline depends on the value of b.
how fast the virus develops resistance to the specific drug), and the initial effectiveness of a
specific drug.
In Figure 6 one can observe the virus load (in logarithmic scale) during the first three weeks
of a treatment with one PI. The three curves correspond to different b’s, the parameter ruling
how fast the virus develops resistance. In all cases one observes a bi-phasic decline; in both
phases the decline is exponential but with sharply different rates. The bi-phasic decline has
been observed during clinical trials and our models can reproduce this feature. In the picture,
one can observe that the beginning of the second (slower) phase, depends on b.
In Figure 7 , again one can see the virus load for a monotherapy with a PI, but with different
initial effectiveness. In this case one can appreciate that the rate of decline during the first
phase of the decline depends on the initial effectiveness.
One observes similar behaviors for the case of a therapy with a RTI.
The picture above suggests that a careful study of the behavior of the virus load during the
first weeks of a therapy could give an estimate on the parameters ruling the dynamics of the
infection, and therefore an indication of the length of the latency period.
5 Conclusions
In this paper we have introduced a model to study the long term behavior of HAARTs (highly
active anti–retrovirus therapies). The basic idea has been to show how in presence of the
treatment the fitness of the viruses is related to the effectiveness of the drug. Assuming that
the fitness of the virus increases through an adaptive mechanism we are able to derive an ODE
((2.12) for the RTI and (2.13) for the PI) that rules the dynamics of the effectiveness of the
drug. The model, implemented in the case of the three-therapies, shows a good qualitative
agreement with the available clinical data. During the first weeks of treatment the virus load
experiences a rapid bi-phasic decline, while the number of the T-cells reaches a level ensuring
good health conditions to the patient. This phase is followed by a latency period during
10
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Figure 7: The behavior of the log of the virus load during the first week of a PI mono-therapy
with different initial effectiveness. The rate of the decline during the first phase depends on
the initial effectiveness. In the picture shown we have taken b = 1× 10−5.
which the condition of the patient remains stable for a period that can last for several years.
The length of the latency period depends on the initial effectiveness of the drugs and on the
parameters ruling how fast the virus develops resistance. Eventually, the latency period ends
and, following a violent virus rebound, the infection returns to the condition preceding the
therapy. This behavior is the typical pattern reported in current medical literature. We notice
the features of this model are robust with respect to variations in our model assumptions;
e.g. one could assume a different power law for the effectiveness in the right hand side of
(2.12) or (2.13) and get the same qualitative behavior of the dynamics, see [17].
To the best of our knowledge this is the first model that describes the whole course of the
therapy, from the initial stages to the insurgence of virus resistance leading to the inefficacy
of the therapy. Should this model be validated from a quantitative point of view, it could be
used as a tool to find the best strategies in modulating the therapy to obtain longer latency
periods whilst minimizing the side effects of the drugs. Apart from the validation of the
model through clinical trials, many problems remain. For example, one could ask what is the
best moment to start the therapy to make the latency period longer. Or take into account
the fact that the drug is taken by the patient discontinuously at specific hours of the day
(and not continuously as assumed by the model). This and other topics will be the subject
of future work.
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